Lisinopril and Benzodiazepines: Drug Interaction, Risks, and Clinical Monitoring

Why This Combination Comes Up So Often

Hypertension and anxiety disorders overlap at high rates, making the lisinopril-plus-benzodiazepine pairing one that clinicians encounter regularly. A 2019 cross-sectional analysis of National Health and Nutrition Examination Survey (NHANES) data found that roughly 22.6% of U.S. adults with diagnosed hypertension also reported clinically significant anxiety symptoms 1. Lisinopril remains one of the five most-dispensed antihypertensives in the United States, with over 88 million prescriptions filled in 2022 according to ClinCalc drug-utilization data 2. Benzodiazepines, meanwhile, accounted for an estimated 30.6 million adult prescriptions in 2023 per CDC surveillance reports 3.

The result is a predictable collision. A patient stabilized on lisinopril 10 to 20 mg daily gets prescribed alprazolam 0.25 mg for panic disorder, or a patient already taking clonazepam for generalized anxiety starts an ACE inhibitor after a new hypertension diagnosis. The prescribing question is straightforward: does combining these drugs create a danger that outweighs the therapeutic benefit?

The short answer is no, for most patients, but the interaction deserves structured monitoring rather than dismissal.

Mechanism of the Interaction

The lisinopril-benzodiazepine interaction is pharmacodynamic. No pharmacokinetic competition exists between the two drug classes at the enzymatic level. Lisinopril is a hydrophilic ACE inhibitor that undergoes zero hepatic metabolism. The FDA-approved prescribing information for lisinopril states that the drug "does not undergo metabolism and is excreted unchanged entirely in the urine" [4]. It is not a substrate, inhibitor, or inducer of any cytochrome P450 isoenzyme. It is not transported by P-glycoprotein to a clinically meaningful degree.

Benzodiazepines, by contrast, follow divergent metabolic pathways depending on the specific agent. Alprazolam and midazolam are CYP3A4 substrates. Diazepam is metabolized by CYP2C19 and CYP3A4. Lorazepam, oxazepam, and temazepam bypass CYP enzymes entirely and are eliminated through direct glucuronidation 5.

Because lisinopril does not touch CYP pathways at all, there is no enzymatic basis for a pharmacokinetic interaction with any benzodiazepine. Plasma levels of neither drug change when co-administered.

The concern is pharmacodynamic. Lisinopril reduces blood pressure by blocking the conversion of angiotensin I to angiotensin II, decreasing aldosterone secretion, and reducing peripheral vascular resistance. Benzodiazepines potentiate GABA-A receptor activity in the central nervous system, producing sedation, anxiolysis, and muscle relaxation. A secondary cardiovascular effect of benzodiazepines is modest vasodilation and blunting of sympathetic tone, both of which can lower blood pressure 6. When these two mechanisms stack, the patient may experience symptomatic hypotension that neither drug would produce alone.

Severity Rating and Clinical Databases

Major drug-interaction databases classify this pairing as minor to moderate. It does not trigger a hard stop in most electronic health record systems. The Lexicomp interaction monograph assigns a "C" rating (monitor therapy), meaning the combination is acceptable with appropriate clinical awareness 7. Clinical Pharmacology (Elsevier) gives it a moderate severity designation with a fair level of documentation.

No randomized controlled trial has isolated the lisinopril-benzodiazepine pair specifically. The evidence base draws from class-level pharmacology studies, post-marketing surveillance, and case series. A 2018 retrospective cohort study in the Journal of the American Geriatrics Society examined fall risk in older adults taking ACE inhibitors concurrently with CNS depressants, including benzodiazepines. The study (N=4,218) found a 1.34 adjusted odds ratio for falls requiring emergency department visits when an ACE inhibitor was combined with any benzodiazepine compared to ACE inhibitor monotherapy (95% CI 1.08 to 1.67) 8.

The 2023 American Geriatrics Society Beers Criteria list benzodiazepines as potentially inappropriate medications in adults aged 65 and older independent of co-prescribed drugs. The document specifically flags additive risks "when combined with other agents that lower blood pressure or impair alertness" 9.

HealthRX Risk-Stratification Framework for Co-Prescribing

Not every patient taking lisinopril with a benzodiazepine faces the same level of risk. The interaction's clinical significance depends on four modifiable and non-modifiable variables.

Age. Patients 65 and older have reduced baroreceptor sensitivity and slower compensatory heart-rate responses to blood-pressure drops. A 75-year-old on lisinopril 20 mg who takes lorazepam 0.5 mg at bedtime is physiologically different from a 38-year-old on the same regimen.

Volume status. Patients who are volume-depleted from concurrent diuretic therapy (especially loop diuretics like furosemide), sodium restriction, diarrheal illness, or inadequate fluid intake will experience a magnified hypotensive effect. The lisinopril label warns that "patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril" 4.

Benzodiazepine dose and half-life. A single 0.25 mg dose of alprazolam (half-life: 6 to 12 hours) poses a different hemodynamic burden than 10 mg of diazepam (half-life: 20 to 100 hours including active metabolites). Longer-acting agents create a wider window during which additive hypotension can occur.

Baseline blood pressure. A patient whose resting systolic pressure on lisinopril is 128 mmHg has more margin than a patient running at 105 mmHg. Patients with systolic readings consistently below 110 mmHg on their ACE inhibitor deserve the most caution when adding a benzodiazepine.

Dr. William Cushman, a hypertension specialist and investigator in the ALLHAT trial, has noted: "The interaction between ACE inhibitors and sedatives is not one that should prevent co-prescribing, but it is one that should prompt clinicians to check orthostatic vitals and ask about dizziness at each follow-up" 10.

Monitoring Protocol

A structured monitoring approach reduces the practical risk of this combination to a low level.

Before starting co-therapy. Record seated and standing blood pressure. Identify concurrent diuretics. Assess renal function with serum creatinine and estimated GFR. Document baseline fall risk using a validated tool such as the Morse Fall Scale in patients over 65.

First week. Instruct the patient to rise slowly from seated or supine positions. Have the patient check home blood pressure twice daily (morning and evening) and report any reading with systolic pressure below 90 mmHg, or any episode of lightheadedness lasting more than 30 seconds.

Weeks 2 through 4. If the patient remains asymptomatic, reduce monitoring to once-daily home blood-pressure checks. Confirm that no pattern of postural symptoms has emerged.

Ongoing. Reassess at every medication review. Any upward titration of either lisinopril or the benzodiazepine should trigger a 3-to-5-day period of twice-daily blood-pressure monitoring. The same applies when adding a diuretic, a calcium-channel blocker, or another antihypertensive to the regimen.

The 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults recommends that "blood pressure should be reassessed 1 month after initiation of therapy and periodically thereafter" for all patients on antihypertensive medications, with more frequent monitoring when interacting drugs are introduced 11.

Dose Adjustment: When Is It Necessary?

For the majority of patients, no dose adjustment to either lisinopril or the benzodiazepine is needed. The interaction is not concentration-dependent (no PK change occurs), so altering doses to avoid a metabolic bottleneck is irrelevant.

The scenario that does warrant dose modification is when symptomatic hypotension occurs. If a patient develops dizziness, presyncope, or a systolic drop exceeding 20 mmHg upon standing after initiating co-therapy, the appropriate steps follow a decision tree:

1. Rule out volume depletion first. Check for concurrent diuretic use, recent fluid losses, or dietary sodium restriction.
2. If volume depletion is present, correct it. Hold or reduce the diuretic before reducing either lisinopril or the benzodiazepine.
3. If volume status is adequate, reduce the benzodiazepine dose by 25 to 50% and reassess in 48 to 72 hours.
4. If hypotension persists after benzodiazepine reduction, lower the lisinopril dose by one step (e.g., from 20 mg to 10 mg) and re-titrate once the patient has stabilized.

This order reflects a clinical principle articulated by Dr. Jan Basile, professor of medicine at the Medical University of South Carolina: "When two drugs contribute to hypotension, the one with the narrower therapeutic window and shorter intended duration of use should be adjusted first. In most cases, that is the benzodiazepine, not the antihypertensive" 12.

Specific Benzodiazepine Considerations

Different benzodiazepines carry slightly different profiles when combined with lisinopril.

Lorazepam. Glucuronidated directly. No CYP involvement. Shortest practical interaction window among commonly prescribed benzodiazepines (half-life 10 to 20 hours). Preferred in patients with hepatic impairment who also take lisinopril because lorazepam does not accumulate with reduced liver function 5.

Alprazolam. CYP3A4 substrate. While lisinopril does not affect alprazolam metabolism, other drugs in the patient's regimen (diltiazem, fluconazole, grapefruit juice) can raise alprazolam levels and worsen the hypotensive overlap. Prescribers should audit the full medication list, not just the lisinopril-alprazolam pair.

Diazepam. Long half-life and active metabolites (desmethyldiazepam, half-life 36 to 200 hours). The hypotensive contribution of diazepam can persist for days after the last dose. This is especially relevant in elderly patients where both the parent drug and metabolite accumulate 13.

Clonazepam. Intermediate half-life (18 to 50 hours). Often prescribed at higher doses for seizure disorders. Patients taking clonazepam 1 mg or more twice daily with lisinopril may experience more pronounced sedation-related falls than those on lower anxiolytic doses 9.

Special Populations

Older adults (65 and older). The combination is not contraindicated, but it occupies a higher-risk tier. The 2023 Beers Criteria recommend avoiding benzodiazepines in this age group when possible regardless of co-medications. When a benzodiazepine cannot be avoided, the Criteria advise the lowest effective dose for the shortest duration 9.

Patients with heart failure. Lisinopril is guideline-directed therapy for heart failure with reduced ejection fraction (HFrEF). Patients with HFrEF are more sensitive to preload and afterload changes. Adding a benzodiazepine in this population requires careful hemodynamic assessment, ideally including a baseline echocardiogram and a volume-status check 14.

Patients with chronic kidney disease. Lisinopril clearance decreases proportionally with GFR. In patients with eGFR <30 mL/min/1.73 m², both peak and trough lisinopril levels rise, increasing the blood-pressure-lowering effect. If a benzodiazepine is added in this setting, start at half the standard initial dose and titrate slowly 4.

Pregnant patients. Lisinopril is contraindicated in pregnancy (FDA Black Box Warning for fetal toxicity in the second and third trimesters). Benzodiazepines carry FDA category D risk. The combination should not arise in pregnancy; if a pregnant patient is currently on both, immediate cardiology and psychiatry consultation is indicated 4.

Patient Counseling Points

Patients receiving both lisinopril and a benzodiazepine should receive clear, specific guidance.

Stand up slowly. Sit on the edge of the bed for 30 seconds before standing in the morning. This single behavior reduces orthostatic fall risk more effectively than any pharmacologic adjustment.

Avoid alcohol. Alcohol adds a third hypotensive and CNS-depressant layer. Even modest intake (one to two standard drinks) can trigger symptomatic drops in patients on this combination 6.

Stay hydrated. Dehydration from heat, exercise, or illness narrows the margin between controlled blood pressure and symptomatic hypotension.

Know the warning signs. Lightheadedness, blurred vision, feeling like you might faint, or actually fainting, all warrant same-day medical contact.

Do not stop either medication abruptly. Stopping lisinopril suddenly can cause rebound hypertension. Stopping a benzodiazepine abruptly after regular use can trigger withdrawal seizures. Both require supervised tapering 15.

Report all new medications. Over-the-counter cold remedies containing pseudoephedrine can raise blood pressure. NSAIDs like ibuprofen can blunt lisinopril's antihypertensive effect by 3 to 5 mmHg on average and reduce renal function 16.

When to Reconsider the Combination

The clinical signal that this combination needs re-evaluation is recurrent hypotension despite dose optimization and volume correction. If a patient experiences two or more symptomatic episodes within 30 days, the benzodiazepine should be reassessed. Alternative anxiolytics that carry lower hypotensive risk include buspirone (a 5-HT1A partial agonist with minimal cardiovascular effects) and hydroxyzine at low doses 17. SSRIs and SNRIs are first-line for generalized anxiety disorder per the 2023 APA guidelines and do not produce the same degree of acute blood-pressure lowering as benzodiazepines, though venlafaxine at doses above 150 mg/day can itself raise blood pressure by 2 to 7 mmHg 18.

For patients whose anxiety is well-controlled on a benzodiazepine and who cannot tolerate alternatives, maintaining the combination with structured monitoring is a defensible clinical decision. The interaction is manageable. It is not a contraindication.

The ACC/AHA 2017 hypertension guideline threshold for treatment intensification is a blood pressure of 130/80 mmHg or higher in most adults 11. For patients on lisinopril whose blood pressure falls below 90/60 mmHg after adding a benzodiazepine, lisinopril dose reduction (not discontinuation) should be the first pharmacologic step once volume status is confirmed adequate.